Brain insulin-like growth factor and neurotrophin resistance in parkinson's disease and dementia with lewy bodies: Potential role of manganese neurotoxicity

Journal of Alzheimer's Disease

Volumn 16, Issue 3, 2009, Pages 585-599

  Tong, Ming ^a   Dong, Matthew ^a   De La Monte, Suzanne M ^a,b  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

Central nervous system; Dementia with Lewy bodies; Human; Insulin like growth factor resistance; Neurotrophin; Parkinson's disease; Receptor ligand binding

Indexed keywords

4 HYDROXYNONENAL; ADENOSINE TRIPHOSPHATE; ALPHA SYNUCLEIN; DOPAMINE BETA MONOOXYGENASE; GLIAL FIBRILLARY ACIDIC PROTEIN; HU PROTEIN; INSULIN; MANGANESE CHLORIDE; NERVE GROWTH FACTOR; NEUROTROPHIN; NEUROTROPHIN RECEPTOR; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UBIQUITIN; CHLORIDE; MANGANESE DERIVATIVE; NERVE GROWTH FACTOR RECEPTOR;

AMYGDALOID NUCLEUS; ANIMAL CELL; ARTICLE; CELL POPULATION; CONTROLLED STUDY; DEMENTIA; FRONTAL CORTEX; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOREACTIVITY; LEWY BODY; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; RAT; REAL TIME POLYMERASE CHAIN REACTION; WHITE MATTER; AGED; ANIMAL; BRAIN; CELL CULTURE; DIFFUSE LEWY BODY DISEASE; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; AGED, 80 AND OVER; ANIMALS; BRAIN; CELLS, CULTURED; CHLORIDES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; LEWY BODY DISEASE; MALE; MANGANESE COMPOUNDS; NERVE DEGENERATION; NERVE GROWTH FACTORS; NEURONS; PARKINSON DISEASE; RATS; RECEPTOR, IGF TYPE 1; RECEPTOR, IGF TYPE 2; RECEPTORS, NERVE GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 65549103889     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-0995     Document Type: Article

References (77)

1. Jellinger KA (2002) Recent developments in the pathology of Parkinson's disease. J Neural Transm Suppl, 347-376.
2. McKeith IG (2000) Clinical Lewy body syndromes. Ann N Y Acad Sci 920, 1-8.
3. Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE (2000) Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 54, 1916-1921.
4. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 95, 6469-6473.
5. Sharma N, McLean PJ, Kawamata H, Irizarry MC, Hyman BT (2001) Alpha-synuclein has an altered conformation and showsatight intermolecularinteractionwith ubiquitininLewy bodies. Acta Neuropathol 102, 329-334.
6. Chung KK, Dawson VL, Dawson TM (2003) New insights into Parkinson's disease. J Neurol 250 Suppl 3, III15-24.
7. Wang HQ, Takahashi R (2007) Expanding insights on the involvement of endoplasmic reticulum stress in Parkinson's disease. Antioxid Redox Signal 9, 553-561.
8. Ostrerova-Golts N, Petrucelli L, Hardy J, Lee JM, Farer M, Wolozin B (2000) The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 20, 6048-6054.
9. Mori H, Hattori N, Mizuno Y (2003) Genotype-phenotype correlation: familial Parkinson disease. Neuropathology 23, 90-94.
10. Warner TT, Schapira AH (2003) Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol 53 Suppl 3, S16-23; discussion S23-15.
11. Gasser T (2000) Autosomal-dominantly inherited forms of Parkinson's disease. J Neural Transm Suppl, 31-40.
12. Hattori N (2002) Parkin gene: its mutations and function. Rinsho Shinkeigaku 42, 1077-1081.
13. Lansbury PT, Jr., Brice A (2002) Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr Opin Genet Dev 12, 299-306.
14. Matsumine H (1999) [A Parkin gene (PARK 2) and Parkinson's disease]. Rinsho Shinkeigaku 39, 9-12.
15. Broussolle E, Thobois S (2002) [Genetics and environmental factors of Parkinson disease]. Rev Neurol (Paris) 158 Spec no 1, S11-23.
16. Hattori N, Mizuno Y (2004) Pathogenetic mechanisms of parkin in Parkinson's disease. Lancet 364, 722-724.
17. Wakabayashi K, Takahashi H (2007) [Pathology of familial Parkinson's disease]. Brain Nerve 59, 851-864.
18. Singh M, Khan AJ, Shah PP, Shukla R, Khanna VK, Parmar D (2008) Polymorphism in environment responsive genes and association with Parkinson disease. Mol Cell Biochem 312, 131-138.
19. von Bohlen und Halbach O, Schober A, Krieglstein K (2004) Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog Neurobiol 73, 151-177.
20. Liu B, Gao HM, Hong JS (2003) Parkinson's disease and exposuretoinfectious agentsand pesticidesand the occurrence of brain injuries: role of neuroinflammation. Environ Health Perspect 111, 1065-1073.
21. Uversky VN (2004) Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res 318, 225-241.
22. Ben-Shlomo Y (1997) The epidemiology of Parkinson's disease. Baillieres Clin Neurol 6, 55-68.
23. Bower JH, Maraganore DM, Peterson BJ, McDonnell SK, Ahlskog JE, Rocca WA (2003) Head trauma preceding PD: a case-control study. Neurology 60, 1610-1615.
24. Newell KL, Boyer P, Gomez-Tortosa E, Hobbs W, Hedley-Whyte ET, Vonsattel JP, Hyman BT (1999) Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxon-al dystrophy and acute traumatic brain injury. J Neuropathol Exp Neurol 58, 1263-1268.
25. Butkovic-Soldo S, Tomic S, Stimac D, Knezevic L, Palic R, Juric S, Marijanovic K (2005) Patients review: drug-induced movement disorders. Coll Antropol 29, 579-582.
26. Shirzadi AA, Ghaemi SN (2006) Side effects of atypical an-tipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry 14, 152-164.
27. Ikeda K, Kashihara H, Tamura M, Kano O, Iwamoto K, Iwasa-ki Y (2007) Body mass index and the risk of Parkinson disease. Neurology 68, 2156; author reply 2156-2157.
28. Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Willett WC, Ascherio A (2004) Obesity and the risk of Parkinson's disease. Am J Epidemiol 159, 547-555.
29. Dulloo AG, Montani JP (2005) Obesity in Parkinson's disease patients on electrotherapy: collateral damage, adiposity rebound or secular trends? Br J Nutr 93, 417-419.
30. Maswood N, Young J, Tilmont E, Zhang Z, Gash DM, Ger-hardt GA, Grondin R, Roth GS, Mattison J, Lane MA, Carson RE, Cohen RM, Mouton PR, Quigley C, Mattson MP, Ingram DK (2004) Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc Natl Acad Sci U S A 101, 18171-18176.
31. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 8, 247-268.
32. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 7, 63-80.
33. de la Monte SM, Tong M, Lester-Coll N, Plater M, Jr., Wands JR (2006) Therapeutic rescue of neurodegeneration in exper- imental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis 10, 89-109.
34. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM (2006) Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis 9, 13-33.
35. Longo FM, Massa SM (2004) Neurotrophin-based strategies for neuroprotection. J Alzheimers Dis 6, S13-17.
36. Olson L, Backman L, Ebendal T, Eriksdotter-Jonhagen M, Hoffer B, Humpel C, Freedman R, Giacobini M, Meyerson B, Nordberg A, et al. (1994) Role of growth factors in degeneration and regeneration in the central nervous system; clinical experiences with NGF in Parkinson's and Alzheimer's diseases. J Neurol 42, S12-15.
37. Unsicker K(1994) Growth factors in Parkinson's disease. Prog Growth Factor Res 5, 73-87.
38. Lindsay RM, Altar CA, Cedarbaum JM, Hyman C, Wiegand SJ (1993) The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease. Exp Neurol 124, 103-118.
39. Betarbet R, Sherer TB, Di Monte DA, Greenamyre JT (2002) Mechanistic approaches to Parkinson's disease pathogenesis. Brain Pathol 12, 499-510.
40. McMillan G (2005) Is electric arc welding linked to mangan-ism or Parkinson's disease? Toxicol Rev 24, 237-257.
41. Antunes MB, Bowler R, Doty RL (2007) San Francisco/Oakland Bay Bridge Welder Study: olfactory function. Neurology 69, 1278-1284.
42. Dick FD, De Palma G, Ahmadi A, Osborne A, Scott NW, Prescott GJ, Bennett J, Semple S, Dick S, Mozzoni P, Haites N, Wettinger SB, Mutti A, Otelea M, Seaton A, Soderkvist P, Felice A (2007) Gene-environment interactions in parkinson-ism and Parkinson's disease: the Geoparkinson study. Occup Environ Med 64, 673-680.
43. Finkelstein MM, Jerrett M (2007) A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities. Environ Res 104, 420-432.
44. Bowler RM, Roels HA, Nakagawa S, Drezgic M, Diamond E, Park R, Koller W, Bowler RP, Mergler D, Bouchard M, Smith D, Gwiazda R, Doty RL (2007) Dose-effect relationships between manganese exposure and neurological, neu-ropsychological and pulmonary function in confined space bridge welders. Occup Environ Med 64, 167-177.
45. Rodriguez-Agudelo Y, Riojas-Rodriguez H, Rios C, Rosas I, Sabido Pedraza E, Miranda J, Siebe C, Texcalac JL, Santos-Burgoa C (2006) Motor alterations associated with exposure to manganese in the environment in Mexico. Sci Total Environ 368, 542-556.
46. McKeith IG, Dickson DW, Lowe J,Emre M, O'Brien JT, Feld-man H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65, 1863-1872.
47. Jellinger KA (2008) Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia. Neurodegener Dis 5, 118-121.
48. de la Monte SM, Jhaveri A, Maron BA, Wands JR (2007) Nitric oxide synthase 3-mediated neurodegeneration after intrac-erebral gene delivery. J Neuropathol Exp Neurol 66, 272-283.
49. Cohen AC, Tong M, Wands JR, de la Monte SM (2007) Insulin and insulin-like growth factor resistance with neurodegenera-tion in an adult chronic ethanol exposure model. Alcohol Clin Exp Res 31, 1558-1573.
50. de la Monte SM, Ganju N, Wands JR (1999) Microtiter Im-munocytochemical ELISA Assay: A Novel and Highly Sensitive Method of Quantifying Immunoreactivity. Biotecniques 26, 1073-1076.
51. de la Monte SM, Xu XJ, Wands JR (2005) Ethanol inhibits insulin expression and actions in the developing brain. Cell Mol Life Sci 62, 1131-1145.
52. Hu JG, Fu SL, Zhang KH, Li Y, Yin L, Lu PH, Xu XM (2004) Differential gene expression in neural stem cells and oligodendrocyte precursor cells: a cDNA microarray analysis. J Neurosci Res 78, 637-646.
53. Kumagai T, Kitagawa Y, Hirose G, Sakai K (1999) Antibody recognition and RNA binding of a neuronal nuclear autoanti-gen associated with paraneoplastic neurological syndromes and small cell lung carcinoma. J Neuroimmunol 93, 37-44.
54. Imai Y, Ibata I, Ito D, Ohsawa K, Kohsaka S (1996) A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. Biochem Biophys Res Commun 224, 855-862.
55. Ito D, Tanaka K, Suzuki S, Dembo T, Fukuuchi Y (2001) Enhanced expression of Iba1, ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain. Stroke 32, 1208-1215.
56. Soscia SJ, Tong M, Xu XJ, Cohen AC, Chu J, Wands JR, de la Monte SM (2006) Chronic gestational exposure to ethanol causes insulin and IGF resistance and impairs acetylcholine homeostasis in the brain. Cell Mol Life Sci 63, 2039-2056.
57. Nagatsu T, Mogi M, Ichinose H, Togari A (2000) Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl, 277-290.
58. Benisty S, Boissiere F, Faucheux B, Agid Y, Hirsch EC (1998) trkB messenger RNA expression in normal human brain and in the substantia nigra of parkinsonian patients: an in situ hybridization study. Neuroscience 86, 813-826.
59. Nagatsu T, Sawada M (2005) Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des 11, 999-1016.
60. Sato S, Mizuno Y, Hattori N (2005) Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology 64, 1081-1083.
61. de la Monte SM, Wells SE, Hedley-Whyte T, Growdon JH (1989) Neuropathological distinction between Parkinson's dementia and Parkinson's plus Alzheimer's disease. Ann Neurol 26, 309-320.
62. Harding AJ, Stimson E, Henderson JM, Halliday GM (2002) Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 125, 2431-2445.
63. Porrino LJ, Crane AM, Goldman-Rakic PS (1981) Direct and indirect pathways from the amygdala to the frontal lobe in rhesus monkeys. J Comp Neurol 198, 121-136.
64. de la Monte SM (1989) Quantitation of cerebral atrophy in preclinical and end-stage Alzheimer's disease. Ann Neurol 25, 450-459.
65. de la Monte SM, Vonsattel JP, Richardson EP, Jr. (1988) Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol 47, 516-525.
66. de la Monte SM, Wands JR (2005) Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis 7, 45-61.
67. Dawbarn D, Allen SJ (2003) Neurotrophins and neurodegen-eration. Neuropathol Appl Neurobiol 29, 211-230.
68. Hock C, Heese K, Muller-Spahn F, Hulette C, Rosenberg C, Otten U (1998) Decreased trkA neurotrophin receptor expression in the parietal cortex of patients with Alzheimer's disease. Neurosci Lett 241, 151-154.
69. Higgins GA, Mufson EJ (1989) NGF receptor gene expression is decreased in the nucleus basalis in Alzheimer's disease. Exp Neurol 106, 222-236.
70. Allen SJ, MacGowan SH, Treanor JJ, Feeney R, Wilcock GK, Dawbarn D (1991) Normal beta-NGF content in Alzheimer's disease cerebral cortex and hippocampus. Neurosci Lett 131, 135-139.
71. Murase K, Nabeshima T, Robitaille Y, Quirion R, Ogawa M, Hayashi K (1993) NGF level of is not decreased in the serum, brain-spinal fluid, hippocampus, or parietal cortex of individuals with Alzheimer's disease. Biochem Biophys Res Commun 193, 198-203.
72. Butterfield DA, Reed T, Perluigi M, De Marco C, Coccia R, Cini C, Sultana R (2006) Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett 397, 170-173.
73. VolkelW,SiciliaT,PahlerA,GsellW,TatschnerT,JellingerK, Leblhuber F, Riederer P, Lutz WK, Gotz ME (2006) Increased brain levels of 4-hydroxy-2-nonenal glutathione conjugates in severe Alzheimer's disease. Neurochem Int 48, 679-686.
74. Zarkovic K (2003) 4-hydroxynonenal and neurodegenerative diseases. Mol Aspects Med 24, 293-303.
75. Camandola S, Poli G, Mattson MP (2000) The lipid peroxidation product 4-hydroxy-2,3-nonenal increases AP-1- binding activity through caspase activation in neurons. J Neurochem 74, 159-168.
76. Hurst JH, LeWitt PA, Burns RS, Foster NL, Lovenberg W (1985) CSF dopamine-beta-hydroxylase activity in Parkinson's disease. Neurology 35, 565-568.
77. Tong ZY, Kingsbury AE, Foster OJ (2000) Up-regulation of tyrosine hydroxylase mRNA in a sub-population of A10 dopamine neurons inParkinson's disease. Brain Res Mol Brain Res 79, 45-54.